HEPA - Dosing underway in higher dose cohort with Hepion's CRV431 in NASH study

Hepion Pharmaceuticals ([[HEPA]] +10.8%) has announced that, in addition to completing dosing in 75mg CRV431 cohort of its Phase 2a AMBITION trial, Hepion has dosed the first non-alcoholic steatohepatitis ((NASH)) patient in 225 mg cohort.The study is designed to assess safety, tolerability, pharmacokinetics and biomarker analyses for early assessments of efficacy of 75 mg and 225 mg CRV431.The company says Phase 2b, another portion the study, is scheduled to commence in 2021.Lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes.

For further details see:

Dosing underway in higher dose cohort with Hepion's CRV431 in NASH study